B. Young

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance

This study identifies secondary splice-site mutations in BRCA1 that drive exon skipping and PARP inhibitor resistance in ovarian and breast cancer.

PAN2-PAN3 deadenylase activity is selectively required for mitotic robustness under microtubule stress

This study shows that PAN2-PAN3 deadenylase activity is required for mitotic robustness under microtubule stress in yeast and human cells.

Genome-wide screen identifies new set of genes for improved heterologous laccase expression in Saccharomyces cerevisiae

The paper screens yeast mutants to identify genes that enhance recombinant laccase secretion, finding that vesicle trafficking and chaperone proteins are critical for improved protein production.

Mutations of SARS-CoV-2 variants of concern escaping Spike-specific T cells

This study examines how mutations in SARS-CoV-2 variants affect Spike-specific T cell responses, finding that some mutations reduce CD8 T cell recognition while overall T cell responses remain largely intact.

Rapid determination of the wide dynamic range of SARS-CoV-2 Spike T cell responses in whole blood of vaccinated and naturally infected

This study evaluates a rapid whole blood test for measuring SARS-CoV-2 Spike-specific T cell responses in vaccinated and infected individuals, finding a wide dynamic range independent of neutralizing antibodies.

Global Genetic Cartography of Urban Metagenomes andAnti-Microbial Resistance

The paper creates a global metagenomic atlas of urban microbial ecosystems, identifying novel species and geographic variation in antimicrobial resistance genes.

The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody

The paper identifies SC31, a potent SARS-CoV-2 neutralizing antibody, and shows that its Fc-mediated effector functions are critical for its therapeutic efficacy in vivo.

Neutralizing antibodies from early cases of SARS-CoV-2 infection offer cross-protection against the SARS-CoV-2 D614G variant.

This study shows that antibodies from early SARS-CoV-2 infections neutralize both the original and D614G variants, though neutralizing capacity decreases over time.

Evidence for strong mutation bias towards, and selection against, T/U content in SARS-CoV2: implications for attenuated vaccine design.

The paper analyzes SARS-CoV-2 mutation patterns to show strong T/U mutation bias and selection against T, suggesting a strategy for vaccine attenuation by increasing usage of common synonymous codons.

Discovery of a 382-nt deletion during the early evolution of SARS-CoV-2

The paper identifies a 382-nt deletion in SARS-CoV-2 ORF8 from Singapore patients, which enhances N gene transcription and may contribute to viral attenuation.

Geldanamycin inhibits Jumonji histone lysine demethylase KDM4 and targets chimeric transcription factor PAX3-FOXO1

This study identifies geldanamycin and its analog 17-DMAG as dual KDM/Hsp90 inhibitors effective against PAX3-FOXO1-driven rhabdomyosarcoma.

Boosting with ALVAC-HIV and AIDSVAX B/E enhances Env constant region 1 and 2 antibody-dependent cellular cytotoxicity

The paper shows that boosting RV144 vaccine recipients with ALVAC-HIV and AIDSVAX B/E increases C1C2-specific antibody-dependent cellular cytotoxicity breadth and potency.